Adaptive Biotechnologies Corp
ADPTQ4 2022(ADPT Q3 FY2022)Estimated10% AI
AI Revenue %
10%
AI Fair Value
$98.0M
AI Revenue (Q)
$4.8M
Total Revenue (Q)
$47.8M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Revenue of $47.8M (single segment). Continuing same methodology. Revenue interest purchase agreement closed in Q3 2022, providing $200M but this is financing, not revenue. Platform described as using computational biology and machine learning, but core revenue from sequencing services and diagnostics.
Analyzed by claude-opus-4-6
Quoted Figures
Revenue $47,830K for three months ended September 30, 2022
10-Q filed 2022-11-08, Income Statement
AI Products Identified (Ring 1)
Immune Medicine TCR-Antigen MapAdaptive Immunosequencing
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic test (NGS-based)MRD Pharma testing services
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix